Tissue Regenix Group

⭐ It is with pleasure to acknowledge a manuscript by N. Bryce Corlee DPM and Vytautas Ringus MD entitled, "𝙎𝙪𝙧𝙜𝙞𝙘𝙖𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙤𝙛 𝙄𝙣𝙨𝙚𝙧𝙩𝙞𝙤𝙣𝙖𝙡 𝘼𝙘𝙝𝙞𝙡𝙡𝙚𝙨 𝙏𝙚𝙣𝙙𝙞𝙣𝙤𝙥𝙖𝙩𝙝𝙮 𝘼𝙪𝙜𝙢𝙚𝙣𝙩𝙚𝙙 𝙒𝙞𝙩𝙝 𝙃𝙪𝙢𝙖𝙣 𝘼𝙘𝙚𝙡𝙡𝙪𝙡𝙖𝙧 𝘿𝙚𝙧𝙢𝙖𝙡 𝙈𝙖𝙩𝙧𝙞𝙭: 𝘼 𝙍𝙚𝙩𝙧𝙤𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚 𝘾𝙖𝙨𝙚 𝙎𝙚𝙧𝙞𝙚𝙨" has been published in the Foot & Ankle Orthopaedics (FAO) Journal. ➡ FAO is a scholarly journal of the American Orthopaedic Foot & Ankle Society (AOFAS). 💡 This manuscript’s protocol for surgical treatment of Insertional Achilles Tendinopathy (IAT) with the use of human ADM allograft augmentation resulted in improved VAS scores and was associated with a low risk of postoperative infection without a prolonged non-weightbearing period. 📚 Please check here for the full publication: https://lnkd.in/gadE-Hbt.

📚 This week’s case study is from Matt Koepplinger, DO, Board Certified, American Board of Orthopaedic Surgery. 🗣 Dr. Koepplinger offered his perspective on the use of DermaPure in this traumatic injury case: “𝘎𝘪𝘷𝘦𝘯 𝘵𝘩𝘦 𝘤𝘰𝘮𝘱𝘭𝘦𝘹𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘰𝘱𝘦𝘯 𝘸𝘰𝘶𝘯𝘥 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘢𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘦𝘥 𝘦𝘹𝘱𝘰𝘴𝘦𝘥 𝘦𝘹𝘵𝘦𝘯𝘴𝘰𝘳 𝘮𝘦𝘤𝘩𝘢𝘯𝘪𝘴𝘮, 𝘭𝘰𝘤𝘢𝘭 𝘤𝘰𝘷𝘦𝘳𝘢𝘨𝘦 𝘰𝘱𝘵𝘪𝘰𝘯𝘴 𝘸𝘦𝘳𝘦 𝘭𝘪𝘮𝘪𝘵𝘦𝘥. 𝘞𝘦 𝘥𝘦𝘴𝘪𝘳𝘦𝘥 𝘤𝘰𝘷𝘦𝘳𝘢𝘨𝘦 𝘰𝘱𝘵𝘪𝘰𝘯𝘴 𝘵𝘩𝘢𝘵 𝘸𝘰𝘶𝘭𝘥 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘴𝘤𝘢𝘳 𝘵𝘪𝘴𝘴𝘶𝘦 𝘢𝘥𝘩𝘦𝘴𝘪𝘰𝘯 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘦𝘹𝘵𝘦𝘯𝘴𝘰𝘳 𝘩𝘰𝘰𝘥 𝘢𝘯𝘥 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘸𝘰𝘶𝘯𝘥 𝘤𝘰𝘯𝘵𝘳𝘢𝘤𝘵𝘶𝘳𝘦. 𝘋𝘦𝘳𝘮𝘢𝘗𝘶𝘳𝘦® 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘥 𝘴𝘶𝘧𝘧𝘪𝘤𝘪𝘦𝘯𝘵 𝘧𝘶𝘭𝘭 𝘵𝘩𝘪𝘤𝘬𝘯𝘦𝘴𝘴 𝘤𝘰𝘷𝘦𝘳𝘢𝘨𝘦 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘵𝘳𝘢𝘶𝘮𝘢 𝘰𝘧 𝘢 𝘥𝘰𝘯𝘰𝘳 𝘴𝘪𝘵𝘦, 𝘢𝘴 𝘸𝘦𝘭𝘭 𝘢𝘴, 𝘳𝘦𝘥𝘶𝘤𝘦𝘥 𝘸𝘰𝘶𝘯𝘥 𝘤𝘰𝘯𝘵𝘳𝘢𝘤𝘵𝘶𝘳𝘦 𝘳𝘪𝘴𝘬 𝘵𝘰 𝘦𝘯𝘢𝘣𝘭𝘦 𝘵𝘩𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘪𝘮𝘱𝘳𝘰𝘷𝘦𝘥 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘧𝘰𝘳 𝘢 𝘮𝘰𝘳𝘦 𝘧𝘶𝘯𝘤𝘵𝘪𝘰𝘯𝘢𝘭 𝘳𝘢𝘯𝘨𝘦 𝘰𝘧 𝘮𝘰𝘵𝘪𝘰𝘯.” 🔗 To learn more about #DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. #decellularisation #dCELL #regenerativemedicine #TRX *The case study contains some graphic content*

📚 This week’s case study is from Mark Ciaglia, DO Board Certified, American Osteopathic Board of Surgeons. Dr. Ciaglia is a hand surgeon in Houston, TX (www.wcfspecialsurgery.com). 🗣 Dr. Mark Ciaglia offered his perspective on the use of DermaPure® in this orthopedic case: "One of the most feared surgical procedures is the reconstruction of the flexor sheath due to the known complications. This is the exact position I was in along with a reconstructed volar plate. I elected to utilize DermaPure to provide supplemental support. The procedure went well and the patient had reduced scarring." 🔗 To learn more about #DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. #decellularisation #dCELL #regenerativemedicine #TRX *The case study contains some graphic content*

📚 This week’s case study is from Jon Minter, DO Board Certified, American Osteopathic Board of Orthopedic Surgeons. 🗣 Dr. Minter offered his perspective on the use of DermaPure® in this orthopedic case: “I found DermaPure® to have exceptional handling characteristics and found it to be quite durable as well. These are two great qualities when repairing soft tissue defects around the knee. It held suture well and I was able to get a “water tight” seal on the former lateral release site.” 🔗 To learn more about #DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. #decellularisation #dCELL #regenerativemedicine #TRX *The case study contains some graphic content*

📚 This week’s case study is from Vytautas Ringus, MD, Board Certified, the American Board of Orthopaedic Surgeons. 🗣 Dr. Ringus offered his perspective on the use of DermaPure® in this orthopedic case: “DermaPure is available in multiple sizes, providing me with flexibility when using it to reinforce tendon repairs." 🔗 To learn more about #DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. *The case study contains some graphic content*

Tissue Regenix reports its unaudited interim results for the six months ended 30 June 2024 delivering continued progress across many areas of the business and marking the Group's eighth consecutive reporting period of growth. Highlights 📈 Group revenues increased by 16% to USD16.4 million 💵 Adjusted EBITDA* profit more than doubled to USD1.1 million 🌟 Profit before taxation of USD0.1 million & gross profit increased to 53% 💰 Cash position of USD3.5 million  ⬆️ A 29% year-on-year increase in tissue processing throughout H1 2024 🏢 Acquired the building in San Antonio that the Company has occupied since 2021 as part of the Phase 1 and 2 expansion plan Jonathan Glenn, Chair of Tissue Regenix Group plc, said: "It has been another impressive half for the Group and I am pleased to report continued success through the execution of the Group's 4S strategy. The management team has done a stellar job of driving the business forward through headwinds in certain segments and continues to identify expansion opportunities geographically as well as through new surgical indications. During H1 2024, there has been continued growth across all business segments and an improvement in profitability from H1 2023. We retain a strong cash position to see us through our current business plans, including the Phase 2 capacity expansion of the Group's facility in San Antonio, which is expected to complete in 2025." Read the full announcement HERE: https://lnkd.in/eSvYXnSB

Tissue Regenix CEO, Daniel Lee and CFO, David Cocke, will be presenting to investors today with an update on the Company's interim results for the six months ended 30 June 2024. The presentation is open to all potential and existing investors and will take place live at 4.30pm (BST). A recording of the presentation will be available shortly after the meeting has concluded. Register for the meeting here: https://lnkd.in/dpWtxJf

Tissue Regenix Group PLC (AIM:TRX) CEO Danny Lee and CFO David Cocke take Proactive's Stephen Gunnion through company’s significant financial progress and strategic growth pillars. Cocke highlighted a strong first half of 2024, with revenues increasing by 16% to $16.4 million. This marks the eighth consecutive growth period, with the gross profit margin rising to 53%, and EBITDA more than doubling to $1.1 million. Notably, the company achieved its first pre-tax profit, a milestone in its history. Discussing the growth drivers, Cocke emphasised the 26% growth in mineralised bone matrix products and the addition of 24 new distributors. The company’s tissue partnerships and regulatory evolution, such as its move to develop medical devices, were key components of the strategy. Watch at #Proactive #ProactiveInvestors http://ow.ly/1KhQ105IcUO

Tissue Regenix CEO, Daniel Lee and CFO, David Cocke, will be hosting a live online presentation relating to the Company's interim results for the six months ended 30 June 2024 on Tuesday 10 September at 4.30pm (BST). Investors can sign up to Investor Meet Company for free and register for the presentation here: https://lnkd.in/dpWtxJf #TRX

 📚 This week’s case study is from Adrienne Denman MD, Board Certified, American Board of Surgeons. 🗣 Dr. Floyd Denman offered her perspective on the use of DermaPure in this pilonidal cyst case: “Pilonidal cyst excisions leave difficult surgical wounds that can be complicated by post-operative wound infection and dehiscence. DermaPure® provides a great matrix for these wounds and aids in the healing process." 🔗 To learn more about DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. *The case study contains some graphic content* #regenerativemedicine #decellularisation #dCELL #TRX #Casestudy #DermaPure